Direct-Acting Oral Anticoagulants
This issue will review the evidence supporting DOACs and their place in therapy for: 1) atrial fibrillation (AF); 2) the acute treatment and long-term secondary prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE); and 3) DVT and PE prevention after major orthopedic surgery and in medically ill patients. The differences among DOACs will be highlighted (eg, side effect profiles, dosing considerations and drug interactions), and DOACs will be compared with warfarin for conditions where both are indicated. Bleeding management and the use of reversal agents will also be addressed.. Read More »
Managing Chronic Pain
Chronic pain management is a global health priority. Millions of adults (11%-19% of the US population) suffer daily from chronic, noncancer pain. A conservative estimate of the economic burden of pain in the US, including both healthcare costs and lost work productivity, is $560 - $635 billion annually. Most patients use a combination of non-drug approaches and medication to help alleviate pain.... Read More »
New Considerations in Diabetes Management
In 2017, the Centers for Disease Control reported that over 30 million people in the US (~10% of the population) have diabetes, including 7.2 million who are undiagnosed. The total estimated cost of diagnosed diabetes in the US was $327 billion in 2017.2 Individuals with diabetes incur average annual medical expenses of about $16,750 – more than twice the expense for people without diabetes.... Read More »
